Applied Neuro Solutions
About Applied NeuroSolutions
Applied NeuroSolutions Team
Research & Development
Articles
Filings & Stock Data
News
Contact Us


CONTACT:
 
Applied NeuroSolutions, Inc.
John F. DeBernardis, Ph.D., President and CEO, 847-573-8000
or
Financial Dynamics
Julie Huang or Courtney Wen (Investors), 212-850-5600
or 
Monarch Communications
Jeff Siegel (Media), 516-569-4271


 

Applied NeuroSolutions’ Founding Scientist Quoted In Investor’s Business Daily (IBD)

 
Vernon Hills, IL
,
January 9, 2006 – Dr. Peter Davies, Applied NeuroSolutions, Inc.’s founding scientist and the Judith and Burton P. Resnick Professor of Alzheimer's Disease Research at Albert Einstein College of Medicine (AECOM), is quoted extensively in an article in today’s issue of Investor’s Business Daily (IBD).

The article, which looks at the enormous market potential for companies focusing on diagnosing and curing Alzheimer’s, quotes Dr. Davies on his views regarding the possible causes of Alzheimer’s and the limited efficacy of current therapeutics.

John DeBernardis, Ph.D., President and Chief Executive Officer of Applied NeuroSolutions stated, “We’re delighted that the mainstream media is increasingly recognizing what most of us in the scientific community have known for a long time – that Dr. Davies is one of the leading scientists in the Alzheimer’s field.”
 

About Applied NeuroSolutions

Applied NeuroSolutions, Inc. (OTCBB:APNS - News) is developing products to diagnose and treat Alzheimer's disease based on a novel hypothesis of AD pathology. In partnership with Dr. Peter Davies and a scientific team at Albert Einstein College of Medicine, Applied NeuroSolutions has developed a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% accuracy in nearly 3,500 patient samples. There are approximately 2 million new patients annually worldwide who are candidates for an AD CSF diagnostic test, according to Datamonitor. The company is also developing a blood serum-based screening test, as well as a new class of therapeutics to treat AD. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan) according to BioPortfolio, Ltd. For more information, visit www.appliedneurosolutions.com.

There are currently no FDA-approved diagnostic tests to detect Alzheimer's disease.

This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.